459 related articles for article (PubMed ID: 17054231)
1. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
2. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
[TBL] [Abstract][Full Text] [Related]
3. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 May; 2010(5):CD005006. PubMed ID: 20464735
[TBL] [Abstract][Full Text] [Related]
4. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
[TBL] [Abstract][Full Text] [Related]
5. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Kremer LC
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD005008. PubMed ID: 26938118
[TBL] [Abstract][Full Text] [Related]
6. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
[TBL] [Abstract][Full Text] [Related]
7. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
de Baat EC; Mulder RL; Armenian S; Feijen EA; Grotenhuis H; Hudson MM; Mavinkurve-Groothuis AM; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014638. PubMed ID: 36162822
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
10. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
[TBL] [Abstract][Full Text] [Related]
11. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Jan; (1):CD006647. PubMed ID: 19160293
[TBL] [Abstract][Full Text] [Related]
12. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
[TBL] [Abstract][Full Text] [Related]
14. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2014 Sep; (9):CD006647. PubMed ID: 25188452
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2005 Jan; (1):CD003917. PubMed ID: 15674919
[TBL] [Abstract][Full Text] [Related]
16. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Jan; (1):CD006647. PubMed ID: 21249679
[TBL] [Abstract][Full Text] [Related]
17. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
18. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
19. Cardiac safety of liposomal anthracyclines.
Ewer MS; Martin FJ; Henderson C; Shapiro CL; Benjamin RS; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):161-81. PubMed ID: 15717742
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2008 Apr; (2):CD003917. PubMed ID: 18425895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]